Targeting this pathway by limiting TREM2 shedding through ADAM10/17 inhibition may represent a promising therapeutic approach for mitigating adipose tissue inflammation and systemic metabolic dysfunction associated with obesity. This evidence concerns the gene ADAM10 and obesity disorder.